Delving into the Latest Updates on Paclitaxel trevatide with Synapse

Overview

Basic Info

Drug Type

Peptide drug conjugates

Synonyms

Angiopep peptide + paclitaxel, Angiopep-2 paclitaxel, Paclitaxel-AngioPep1-conjugate-Angiochem

+ [5]

Target

LRP1 x Tubulin

Mechanism

LRP1 modulators(LDL receptor related protein modulators), Tubulin inhibitors, Mitosis inhibitors

Therapeutic Areas

NeoplasmsNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

HER2-negative breast cancerMeningeal CarcinomatosisMetastatic Malignant Neoplasm to the Leptomeninges+ [4]

Inactive Indication

Advanced Malignant Solid NeoplasmMetastatic human epidermal growth factor 2 positive carcinoma of breastmetastatic non-small cell lung cancer+ [1]

Originator Organization

Angiochem, Inc.

Active Organization

Angiochem, Inc.XINOGEN （HONG KONG） PHARMA CO., LIMITED

Beijing Shenogen Pharma Group Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 49342

Source: *****

Compare the overall survival (OS) between the two groups; Compare the intracranial and extracranial progression-free survival (PFS) between the two groups; Compare the intracranial and extracranial objective response rate (ORR) between the two groups; Compare the intracranial duration of response (DoR) and DCR at 3 and 6 months between the two groups; Compare the extracranial DoR between the two groups; Compare the overall QoL between the two groups

Start Date24 May 2022

Sponsor / Collaborator

XINOGEN （HONG KONG） PHARMA CO., LIMITED

[+1]

100 Clinical Results associated with Paclitaxel trevatide

Login to view more data

100 Translational Medicine associated with Paclitaxel trevatide

Login to view more data

100 Patents (Medical) associated with Paclitaxel trevatide

Login to view more data

123

Literatures (Medical) associated with Paclitaxel trevatide

01 Mar 2025·BIOMATERIALS

Metal-organic framework-edaravone nanoparticles for radiotherapy-induced brain injury treatment

Article

Author: Ding, Zhongxiang ; Li, Xuejiao ; Hua, Shiyuan ; Zhou, Min ; Zhong, Danni

Cranial radiotherapy may cause damage to normal brain tissues and induce cognitive dysfunction, so developing an effective strategy to prevent radiotherapy-induced brain injury is essential. Metal-organic frameworks (MOFs) can be used as vectors for the delivery of neuroprotective drugs due to their high drug loading capacity and low toxicity. In this study, we synthesized MIL-53(Cr) nanoparticles, which were used to deliver edaravone, and modified the surface of the nanoparticles with polyethylene glycol and Angiopep-2 (EDA@MIL-53(Cr)-P/A) to improve their oral bioavailability and ability to cross the blood-brain barrier (BBB). We confirmed that MIL-53(Cr)-P/A nanoparticles could achieve the sustained release of edaravone and enhance its ability to cross the BBB. The results of in vitro experiments showed that EDA@MIL-53(Cr)-P/A could exert radioprotective effects on HT22 and BV2 cells. We also demonstrated that EDA@MIL-53(Cr)-P/A could alleviate brain injury and cognitive dysfunction in mice receiving whole-brain irradiation. Mechanistically, EDA@MIL-53(Cr)-P/A alleviated irradiation-induced brain damage by inhibiting oxidative stress, DNA damage, apoptosis and inflammatory reactions. This study provides a new strategy for the protection against radiotherapy-induced brain injury.

04 Feb 2025·ACS Nano

Engineered Extracellular Vesicles Modified by Angiopep-2 Peptide Promote Targeted Repair of Spinal Cord Injury and Brain Inflammation

Article

Author: Wang, Juan ; Wang, Siming ; Tang, Chunming ; Li, Cong ; Xiong, Wu ; Deng, Mingyang ; Liu, Minhao ; Liu, Jie ; Kong, Guang ; Fan, Jin ; Yu, Xiaohu

Engineered extracellular vesicles play an increasingly important role in the treatment of spinal cord injury. In order to prepare more effective engineered extracellular vesicles, we biologically modified M2 microglia. Angiopep-2 (Ang2) is an oligopeptide that can target the blood-brain barrier. Through single-cell sequencing and immunofluorescence experiments, we confirmed that the expression of LRP-1, the targeted receptor of Ang2, was elevated after spinal cord injury. Subsequently, we integrated the Ang2 peptide segment into M2 microglia to obtain Ang2-EVs, which could successfully target the site of spinal cord injury. However, in order to improve the function of Ang2-EVs, we pretreated M2 microglia with melatonin, which has anti-inflammatory effects, to obtain M-Ang2-EVs. The results of single-nucleus sequencing of the mouse spinal cord verified that neurons and OPCs gradually transformed into subtypes related to nerve repair functions after treatment with M-Ang2-EVs. This is consistent with the sequencing and enrichment analysis of miRNAs contained in M-Ang2-EVs. We further verified through experiments that M-Ang2-EVs can promote microglia/macrophages to phagocytose sphingomyelin, promote axon remyelination and axon elongation, and maintain the integrity of the blood-spinal barrier. Since Ang2 can also target the blood-brain barrier, we found that M-Ang2-EVs can also reduce brain inflammation that results from spinal cord injury. Our study applied the Angiopep-2 peptide to spinal cord injury to enhance the targeting of injured cells, and successfully construct engineered extracellular vesicles that can target the spinal cord injury site and the brain.

01 Dec 2024·Drug Delivery and Translational Research

Chemical engineering of zein with polyethylene glycol and Angiopep-2 to manufacture a brain-targeted docetaxel nanomedicine for glioblastoma treatment

Article

Author: Faria, Paulo ; Araújo, Marco ; Awad, Seem ; Sarmento, Bruno ; Martins, Cláudia

Abstract:

Glioblastoma (GBM) is the deadliest adult brain cancer. The current standard-of-care chemotherapy using orally administered temozolomide (TMZ) presents poor improvement in patient survival, emphasizing the compelling need for new therapies. A possible chemotherapeutic alternative is docetaxel (DTX), which possesses higher tumoricidal potency against GBM cells. However, its limited blood-brain barrier (BBB) permeability poses a constraint on its application. Nonetheless, nanomedicine offers promising avenues for overcoming this challenge. Angiopep-2 (ANG2) is a peptide that targets the BBB-overexpressed low-density lipoprotein receptor (LDLR). In this work, we managed, for the first time, to employ a pioneering approach of covalently linking zein protein with polyethylene glycol (PEG) and ANG2 prior to its formulation into nanoparticles (ZNPs) with enhanced stability and LDLR-mediated brain targetability, respectively. Carbodiimide and click chemistry approaches were optimized, resulting in functional modification of zein with around 25% PEG, followed by functional modification of PEG with nearly 100% ANG2. DTX-loaded ZNPs presented 100 nm average size, indicating high suitability for BBB crossing through receptor-mediated transcytosis. ZNPs maintained the cytotoxic effect of the loaded DTX against GBM cells, while demonstrating a safe matrix against BBB cells. Importantly, these brain-targeted ZNPs showcased up to fourfold enhancement in blood-to-brain permeability in a BBB in vitro model, highlighting the potential of this novel approach of BBB targeting in significantly improving therapeutic outcomes for GBM patients. The versatility of the system and the possibility of significantly increasing drug concentration in the brain open the door to its future application in a wide range of other brain-related diseases.Graphical abstract

1

News (Medical) associated with Paclitaxel trevatide

07 Dec 2023

·www.prnewswire.com

Leptomeningeal Disease Pipeline Insights: 2023 Analysis Reveals Advancements in Global Cancer Treatment Developments

DUBLIN, Dec. 7, 2023 /PRNewswire/ -- The "Leptomeningeal Disease - Pipeline Insight, 2023" report has been added to ResearchAndMarkets.com's offering. This comprehensive analysis provides an in-depth view of the ongoing developments and future prospects in the therapeutic landscape of Leptomeningeal Disease (LMD), a serious complication that results from cancer cells spreading to the cerebrospinal fluid (CSF). This report is an indispensable resource for anyone interested in the evolving market dynamics and the potential of emerging therapies confronting this challenging medical condition. Unveiling the Scope of Leptomeningeal Disease Research: The report delineates the concerted efforts by pharmaceutical companies and academic researchers who are at the forefront of offering novel solutions to improve the management and therapeutic outcomes of LMD. With a focus on over seven companies and seven pipeline drugs, the document offers a detailed assessment of clinical and nonclinical stage products along with a meticulous analysis of their mechanism of action, clinical studies, and development activities. Emerging Therapies Highlighted: The spotlight is cast on promising candidates like ANG1005 by Angiochem Inc, poised to make a significant impact in LMD treatment. This drug showcases a novel approach by leveraging mechanisms to traverse the blood-brain barrier (BBB)—a profound breakthrough. Moreover, Kazia Therapeutics' Paxalisib represents an innovative PI3K/AKT/mTOR pathway inhibitor in Phase I evaluation, demonstrating the continuous evolution of targeted therapy in this realm. Therapeutic Assessment by Varied Parameters: Detailed Leptomeningeal Disease commercial and clinical assessment. Therapeutics segmentation by product type, developmental stage, route of administration, and molecule type. In-depth analysis of late-stage (Phase III) products. Insights into pipeline development activities and strategic collaborations. The document sets forth a thorough analysis of the pipeline landscape, also evaluating therapies across different stages such as Phase II and I trials. It incorporates a granular examination of the therapies, stratifying them based on administration routes ranging from oral to intrathecal, and classifies them under small molecules, peptides, and other categories. Furthermore, it investigates the intricate details of the product development process, from collaborations, acquisitions, and mergers, to the vital designations granted to drugs in the pipeline. The "Leptomeningeal Disease -Pipeline Insight, 2023" report is a testament to the enduring commitment to equipping industry participants with the knowledge required to navigate the complex terrain of cancer-related central nervous system complications. As the medical community endeavors to improve the prognosis and quality of life for patients afflicted with LMD, such comprehensive research analyses become not just tools for enlightenment, but beacons of hope. For those seeking a thorough understanding of the perspectives and progress in the treatment of Leptomeningeal Disease, this report is an indispensable resource. Interested parties are encouraged to explore the depth of research and analysis presented, shedding light on the future trajectory of therapeutics in this critical field of oncology. Companies profiled in the report include: Angiochem Kazia Therapeutics Mustang Bio Y-mAbs Therapeutics Plus Therapeutics For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Phase 1ASCOFast Track

100 Deals associated with Paclitaxel trevatide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Paclitaxel trevatide	-	DB06171

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Meningeal Carcinomatosis	Phase 3	-	Angiochem, Inc.	01 Dec 2023
Metastatic Malignant Neoplasm to the Leptomeninges	Phase 3	-	Angiochem, Inc.	01 Dec 2023
HER2-negative breast cancer	Phase 3	CN	XINOGEN （HONG KONG） PHARMA CO., LIMITED	12 Aug 2022
HER2-negative breast cancer	Phase 3	CN	Beijing Shenogen Pharma Group Ltd.	12 Aug 2022
Brain metastases	Phase 3	CN	Beijing Shenogen Pharma Group Ltd.	24 May 2022
Brain metastases	Phase 3	CN	XINOGEN （HONG KONG） PHARMA CO., LIMITED	24 May 2022
HER2 Positive Breast Cancer	Phase 3	CN	XINOGEN （HONG KONG） PHARMA CO., LIMITED	24 May 2022
HER2 Positive Breast Cancer	Phase 3	CN	Beijing Shenogen Pharma Group Ltd.	24 May 2022
Neoplasms	Phase 3	CA	Angiochem, Inc.	30 Jan 2022
Glioblastoma	Phase 3	-	Angiochem, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01967810 (Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005, Pubmed \| Neurooncol Adv)	Phase 2	Recurrent Malignant Glioma	73	ANG1005 600 mg/m2	zmvoerwrkm(cwptwdylxf) = vamydvbyay jmasaabwig (baimafmmzl, 1.4 - 2.1) View more	Negative	01 Jan 2024
	Phase 2	Recurrent Malignant Glioma	73	Bevacizumab	qmsqwjimnx(qthmuyeyyv) = lfyoakzjnw vskqjxgyal (jhkurywiks, 1.9 - 9.7)	Negative	01 Jan 2024
P1-12-01 (SABCS2017)	Phase 2	Breast cancer recurrent HER2+	72	ANG1005 600 mg/m2 q3w	xbbhmjiant(wpkivaojfw) = feepmkfzyw lqzwosgzic (cxgnbgexyh, 37.4 - 61.6) View more	-	15 Feb 2017
BMET-28 (SNO2016)	Phase 2	Breast cancer recurrent HER2+	28	ANG1005 600mg/m2 q3w	gtnykewnqd(bpuabzvsht) = yguyfegogv pwwejrraza (tuwhatspvr, 42.9 - 78.5)	Positive	07 Nov 2016
NCT01497665 (GRABM-L, CTgov)	Phase 2	metastatic non-small cell lung cancer \| Brain metastases	16	GRN1005	djvmribmvc(sjkjmivgfm) = cpeubkhpvi kglzgbwewn (bahvwsmigq, ecqttullec - cigcovbewd) View more	-	14 Dec 2015
BMET-23 (SNO2015)	Not Applicable	Breast Cancer HER2+	-	ANG1005 600 mg/m2 q21d	sozwxxuwbz(yxgtyyctxl) = myelosuppression as the predominating toxicity okvmtqyqki (xzmmlavvsc )	Positive	09 Nov 2015
NCT01480583 (ASCO2015)	Phase 2	Brain metastases	85	ANG1005	jmjaiuxxce(xaydebnzzu) = wokbfquoyp qavedntodm (flahkymgqd ) View more	-	20 May 2015
Pubmed \| Mol Cancer Ther	Not Applicable	Advanced Malignant Solid Neoplasm	-	GRN1005	lasxuwylob(dtpysmwscc) = lhzvahgviy khgriojebu (ifgkhywdja ) View more	-	01 Feb 2012
ASCO2010	Phase 1	Recurrent Malignant Glioma	63	ANG1005	eyastcrwoi(vkoxrvfzky) = ndroakurzq gplooykyyr (nrdsntnmpi )	Positive	20 May 2010